Familial hypertrophic cardiomyopathy (FHC) is an autosomal dominant disease of the sarcomere with well over 100 associated mutations in 9 sarcomeric proteins, including cardiac troponin I (cTnI). 1,2 cTnI is a small peptide (210 residues) that, together with troponin C and troponin T, forms the troponin complex. In striated muscle, this complex, which is associated with the thin filament, forms the major calcium sensor and, thus is responsible for controlling the thick-thin filament interactions that result in the contractile cycle. Troponin I is bound to cardiac troponin C (cTnC) in an antiparallel fashion such that its amino terminus associates with the carboxyl terminus of cTnC. cTnI differs from the slow skeletal isoform of TnI by a 32 amino acid extension at the cTnI amino terminus. Two serine residues that are substrates for protein kinase A (PKA) lie within this extension. 3, 4 cTnI is also sensitive to protein kinase C phosphorylation at serines 43 and 45 and threonine 143. 5 The effect of cTnI phosphorylation is primarily a downward modulation of cardiac contractility, either by decreased ATPase activity, which is mediated by PKC, or by increased binding of cTnI to the thin filament, mediated by PKA. A truncation of cTnI (cTnI ) has been associated with myocardial stunning, 6, 7 and measuring the serum level of cTnI has become the standard of care in the diagnosis of myocardial injury. 8 -12 The so-called inhibitory region of cTnI is an 11 amino acid motif that is evolutionarily conserved (Figure 1 ). This region alternatively binds to either the thin filament or cTnC, depending on the intracellular concentration of calcium ([Ca 2ϩ ] i ). High [Ca 2ϩ ] i values promote Ca 2ϩ binding to cTnC, facilitating a shift of the inhibitory region of cTnI from the thin filament to cTnC. This produces positional changes in the actin-tropomyosin conformation and promotes the transition from weakly bound to strongly bound actin-myosin crossbridges, leading to ATP hydrolysis. 13 During diastole, when [Ca 2ϩ ] i is low, the inhibitory region of cTnI remains bound to the thin filament, suppressing the power stroke. Therefore, cTnI is a critical element, transmitting the systolic and diastolic variations in [Ca 2ϩ ] i to the sarcomere. Mutations that can cause FHC have been defined in 3 different domains of cTnI: 2 mutations in the inhibitory domain, 1 in the C-terminal domain, and 4 in the protein's distal region. Patients with the inhibitory region mutations or one of the distal mutations (L206Q) develop the characteristic ventricular hypertrophy of FHC. In contrast, patients carrying the other cTnI mutations develop hypertrophy only at the cardiac apex. 1, 2 To begin exploring the functional significance of a single amino acid mutation in the inhibitory region of cTnI, we generated transgenic (TG) mice that express the R145G (R146G in the mouse sequence) mutation. This mutation replaces a positively charged arginine with an uncharged, polar glycine residue. The consequences of the altered structure-function relationships of the cardiac calcium sensor were subsequently determined at the molecular, cellular, and whole organ levels.
Materials and Methods

Transgene Construction
All experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee. Three TG constructs were used. The wild-type (wt) cDNA for mouse cTnI was obtained by reverse transcription-polymerase chain reaction using total RNA isolated from mouse cardiac ventricle as template. The 5Ј primer contained a portion of the cTnI 5Ј untranslated region (5Ј-GGGGAGGAGACAGCAGTATATTTAG-3Ј), whereas the 3Ј primer was made complementary to the 3Ј untranslated region (5Ј-GAGGTTTATTCTGCAGGGACGTCC-3Ј). The wt cDNA was subcloned into pBluescript and sequenced in full. The TnI 146Gly mutation was created using standard polymerase chain reactionbased methods. A third cDNA was generated that included a FLAG tag 14, 15 inserted at the amino terminus just distal to the translational start site of the wt cDNA. The 3 cDNAs (TnI 146Gly , wt, and wt-tagged) were separately subcloned into the mouse ␣-myosin heavy chain (␣-MHC) promoter (Figure 1) , and the purified DNA was used to generate multiple lines of TG mice. 16 
Phenotype Analyses
Except where noted, 3 to 6 animals of mixed gender were used for our studies after preliminary experiments showed no gender differences. For assessment of cTnI 146Gly and cTnI wt transcript size, Northern blot analysis was performed using 7.5 g of total RNA, as described. 17 Expression levels were determined by RNA dot blot analysis with a 32 P-labeled oligonucleotide (5Ј-GCGTGTGGCTCG-GTGGCATAGGCTCGGTAGTTGGCAGAGGAGCGGCGTCGGA -CAGG-3Ј). Molecular markers of hypertrophy were examined by RNA dot blot analysis using 32 P-labeled oligonucleotides, as described. 18 -20 Two to three TG and non-TG (NTG) mice from each line were analyzed, and statistically significant differences were determined by unpaired Student's t test, with significance defined as PՅ0.05.
Western blot analysis of ventricular myofibrils was performed using a cTnI-specific affinity purified polyclonal antibody (Research Diagnostics, Inc) and a peroxidase-conjugated donkey antigoat IgG secondary antibody (Jackson ImmunoResearch Laboratories). Five micrograms of myofibrils was subjected to SDS-PAGE, transferred to polyvinylidene fluoride membrane (BioRad), and incubated with primary antibody (1:5000) and secondary antibody (1:10000). Immunofluorescence was analyzed with a STORM 820 imager (Molecular Dynamics). The percentage of TG replacement was calculated as FLAG-tagged cTnI/(FLAG-tagged cTnIϩendogenous cTnI). The percentage of TG protein replacement was plotted as a function of transcript overexpression.
Structural analyses at the light and electron microscopy levels were performed as described. 21 Using 2 to 4 mice of mixed gender, multiple sections were cut and Ͼ50 fields were observed. To assess the pattern of the FLAG-tagged cTnI incorporation into the sarcomere, isolated cardiomyocytes 22 were examined by confocal microscopy with anti-FLAG M2 monoclonal antibody (Sigma), M.O.M. biotinylated antimouse IgG, and Texas Red Avidin D (Vector Laboratories).
Functional assays included skinned fibers analysis, described in detail elsewhere. 23 Skinning was carried out essentially as described by Strang et al, 24 who noted previously in these preparations that the myofibril proteins are not phosphorylated. All experiments were performed using a commercially available apparatus (Scientific Instruments). Strip tension (mN/mm 2 ) was determined by dividing force by fiber cross-sectional area (calculated from widths measured at the major axis). Isolated working heart function was also determined, as previously described. 25 
Results
Generation of Mice Carrying Troponin I Transgenes
Three constructs were used to generate multiple lines of TG mice ( Figure 1 ). To rule out any phenotype attributable to overexpression of TnI, lines carrying the wt cDNA were made, and one was selected for analysis (line 52) whose cTnI RNA level exceeded that of the cTnI 146Gly lines used. A total of 4 lines carrying the TnI 146Gly transgene were analyzed. Two of these, lines 135 and 141, could not be studied in detail because of the paucity and early death of TG offspring. In fact, the founders died prematurely and had grossly abnormal hearts (data not shown). The remaining 2 lines (121 and 133) were selected for analysis. RNA overexpression levels for lines 121 and 133 were 1.2-fold and 3.5-fold higher, respectively, compared with endogenous cTnI RNA. Line 52 expressed the wt transcript at 5-fold the endogenous level. In previous experiments using the ␣-MHC promoter to drive expression of TG contractile transcripts, levels of transgene expression varied by 1-to 15-fold 16, 18, [23] [24] [25] and sometimes more. 21 The relatively low and narrow range of TG expression in the cTnI 146Gly lines suggested that potential founders with high TG expression may not have survived to birth. Supporting this hypothesis, mice from the highest expressing line, 133 (with 3.5-fold greater expression relative to the endogenous transcript), died between 13 and 17 days after birth and had markedly abnormal hearts.
Despite a relatively narrow range of expression, differences in morbidity and mortality presented. Line 121 had no overt phenotype in early adulthood, although females stressed by pregnancy did develop cardiac pathology (see below). However, life expectancy in this line did not differ appreciably from normal animals ( Figure 2 ). Expression of wt cTnI at 5-fold the level of the endogenous message (line 52) resulted in a cohort of mice with normal survival (Figure 2A ). Breeding line 121 TG mice to one another doubled transgene expression to 2.4-fold and resulted in death of the animals carrying a double dose of the transgene at 18 to 26 days. Transgenic mice from line 133, with 3.5-fold overexpression at the transcript level, did not survive past 17 days. Although some aspects of a hypertrophic response were observed at the molecular level, no increases in the ventricle or body weights were detected in the adult cTnI 146Gly animals ( Figure 2B ).
RNA and Protein Expression in TG Animals
We wished to determine whether animals displaying early lethality showed any abnormalities in RNA expression in the heart, reminiscent of the altered patterns that have been observed in other models of cardiac disease. 20 At the RNA level, line-133 mice at 10 days after birth (Ϸ3 to 7 days before death) exhibited aspects of the expression pattern observed in adult hearts undergoing a hypertrophic response at the molecular level. Relative to NTG animals, atrial natriuretic factor and ␣-skeletal actin transcripts were elevated, whereas SERCA2 and phospholamban transcripts were decreased ( Figure 3 ). Line 121 and the wt cTnI-expressing line 52 were analyzed at 4 to 5 months of age. Line 121 only showed upregulation of atrial natriuretic factor, consistent with the milder phenotype, whereas the animals that expressed the wt TnI transgene did not differ from NTG animals. The changes observed in contractile protein isoform expression, although striking, were not consistent with the resultant mortality. We wished to see if any major changes in the contractile apparatus had occurred as a result of cTnI 146Gly expression. Extensive experience has shown that robust TG expression of a sarcomeric protein does not affect myofibril stoichiometry. 16, 18, 21, [23] [24] [25] This finding was confirmed in the TnI mice, with no alteration in the absolute amounts of cTnI ( Figure 4A ) or contractile protein stoichiometry in any of the animals studied (data not shown). No changes in the MHC isoforms were observed, consistent with the lack of a full hypertrophic response (Figures 2 and 3 ). Attempts to separate cTnI 146Gly from the endogenous protein were unsuccessful, prohibiting the direct determination of mutant cTnI incorporation into the sarcomere. To correlate the amount of TG protein substitution with the degree of overexpression at the transcript level, an additional construct, wt cTnI with an epitope FLAG tag (Figure 1) , was used to generate TG mice. Previous experiments in which sarcomeric proteins were expressed showed a linear relationship between the level of TG RNA expression and the degree of protein replacement. 18 Thus, by comparing the level of TG overexpression determined by RNA dot blot analysis to the percentage of replacement of endogenous cTnI by tagged cTnI (determined by Western blotting), we were able to generate an equation describing the relationship of RNA expression to TG protein replacement (Figures 4B and 4C) . No unincorporated FLAGtagged cTnI was detected by confocal microscopy ( Figure   Figure 2 . Kaplan-Meier survival curves. The degree of transgene overexpression relative to endogenous cTnI expression is indicated. Between 7 to 17 mice per line of mixed gender were available for each cohort. Mice from the FLAG-tagged lines were killed for analysis at 4 to 6 weeks of age and are not represented on this graph. B, Representation of atrial weight/body weight (AW/BW) and ventricular weight/body weight (VW/BW) ratios in mg/gm. Line-133 animals were 10 to 11 days of age, whereas line-121 animals were 6 to 10 weeks of age. The slightly smaller ventricles in the adults are probably attributable to reduced cardiomyocyte size, which has been observed in related transgenic models. 31,35 *PϽ0.01. 4D), indicating that Western blot analysis of myofibrillar protein accumulation accurately represents the amount of TG protein present in cardiomyocytes. Assuming that FLAGtagged cTnI, cTnI 146Gly , and cTnI(wt) incorporate into myofibrils with equal efficiency, we estimated that the cTnI complement of line 133, with the highest level of cTnI 146Gly TG overexpression, consisted of Ϸ50% of mutant protein, whereas lines 121 and 52 had 40% and 60% replacement, respectively, of endogenous cTnI with TG cTnI. (Figure 4C ).
At 18 days of gestation, the TG and NTG ventricles of the highest expressor, line 133, were indistinguishable from one another, a result consistent with the lack of TG expression in the ventricle at this developmental stage ( Figure 5A ). However, by 10 days after birth the ventricles demonstrated cardiomyocyte disarray, interstitial and perivascular fibrosis, and nuclear degeneration ( Figure 5B ). This line could not be examined at later stages because of death at 13 to 17 days. Male and nulliparous female TG mice from the lowerexpressing line 121, had no discernible pathology at any age (data not shown). However, 13-month postpartum females showed cardiomyocyte hypertrophy as well as patchy areas of interstitial and perivascular fibrosis ( Figure 5C ). Line-52 TG mice (wt overexpressors) were indistinguishable from NTG littermates (data not shown). Thus, the effects of cTnI 146Gly on the myocardium seem to be dose-dependent such that the highest expressing line showed accelerated pathological changes and a decreased life expectancy, whereas line 121 demonstrated abnormalities only after the physiological stress of pregnancy.
Ultrastructural changes in lines 121, 133, and 52 were documented ( Figure 6 ). In comparison with age-matched NTG littermates ( Figure 6A ), 9-day-old line-133 TG mice 
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had abnormally short sarcomeres (Ϸ1 to 1.5 m), with wide Z bands and no visible I bands ( Figure 6B ). Sarcomeric organization was disturbed in many areas and completely lacking at isolated foci. The sarcoplasmic reticulum (SR) was swollen and disorganized, with disruption of the normal spatial relationship between the sarcomeres and SR. The mitochondrial ultrastructure and distribution was likewise abnormal. A representative field from a line-121 parous female revealed features of hypoxia in some cardiomyocytes, as evidenced by swollen mitochondria and large gaps between the SR, mitochondria, and sarcomeres. The interstitium contained small amounts of collagen fibers ( Figure 6C ). Line 52 could not be distinguished from NTG littermates (data not shown). We hypothesized that cTnI 146Gly expression would have direct effects on both fiber mechanics and kinetics. The pCa-force relationship was determined using dephosphorylated skinned papillary muscle strips from cTnI 146Gly line 133 at 10 days after birth. A significant increase in Ca 2ϩ sensitivity compared with NTG littermate controls was observed, and maximum tension (P0) was significantly depressed ( Figure  7A ). There were no differences detected in unloaded shortening velocity, maximum shortening velocity, or maximum relative power (data not shown). We also studied the less affected animals, line 121, at 6 weeks of age and again found increased Ca 2ϩ sensitivity and significantly decreased P0 ( Figure 7B ). As with line 133, line 121 did not have alterations in unloaded shortening velocity, maximum shortening velocity, or maximum relative power (data not shown). Line 52 was indistinguishable from NTG animals ( Figure 7B) .
To examine the consequences of cTnI 146Gly on whole heart function, lines 121 and 52 were studied using the isolated working heart preparation 18 (Table) . Line 133 could not be analyzed because of early death. Line 52 did not differ significantly from NTG littermate controls. However, the striking differences in both ϩdP/dt and ϪdP/dt in line 121 was surprising given the otherwise mild manifestations of cardiac pathology at the molecular and microscopic levels. Contractility was significantly enhanced, whereas relaxation was impaired. The time constant of relaxation, , a load-independent measure of diastolic function, was markedly prolonged in TG mice from line 121. Thus, expression of cTnI 146Gly in the mouse heart results in enhanced systolic function but compromised diastolic function.
Discussion
There are few data concerning the relative morbidity and mortality of the cTnI mutations in humans. Three of the 7 mutations (R145G, R145Q, and L206Q) resulted in a typical hypertrophic cardiomyopathy, 1 (K183del) caused apical hypertrophy in one family member and typical hypertrophy in another, and 3 (R162W, S199N, and G203S) caused apical hypertrophy resulting in a spadeshaped ventricle. 1,2 In 9 family members carrying S199N, 2 experienced sudden death in the sixth decade, 6 others had varying symptoms (arrhythmia or left ventricular dysfunction), and 1 was asymptomatic at 21 years of age. 2 Our work describes the effects of the cTnI 146Gly mutation in mice. Consistent with the presentation of many of the pathological features of typical FHC, the mice exhibited myofibrillar disarray, and interstitial fibrosis; some of the molecular markers of cardiac hypertrophy are activated although no overt hypertrophy, as measured by increases in ventricle mass/body mass were observed. At the whole organ level, contractile function is enhanced but relaxation is compromised. Because cTnI binds to both cTnC and actin, it seems likely that the primary etiology of cardiac dysfunction in the cTnI 146Gly mice lies in altered cTnI interactions with cTnC, actin, or both. Certainly, different cTnI isoforms can modulate the effective cross bridge detachment rate. 26 The binding of the inhibitory domain of cTnI to actin inhibits actomyosin ATPase activity, depresses cross-bridge cycling, and prevents contraction. The inhibition is released as cTnI binding shifts from actin to cTnC, an action favored by an increase in [Ca 2ϩ ] i during systole, when Ca 2ϩ binds to cTnC. This alters the tertiary structure of cTnC and exposes a hydrophobic pocket in the amino terminus of protein. It is here that the inhibitory region of cTnI binds, allowing movement of tropomyosin on actin, exposing the myosin binding site, and promoting contraction. Augmented contractility and depressed relaxation in the working heart are consistent with in vitro data obtained using purified, recombinant human cTnI. The decreases observed in maximal tension, although inherently contradictory with the hypothesis that the switch is in the "on" position, may well be accounted for by the myocyte dropout that we observed in these animals ( Figure  5 and data not shown). Functional abnormalities, which included a reduced ability to inhibit the actin-tropomyosin-activated ATPase as well as an increase in Ca 2ϩ sensitivity, 27 suggest that cTnI 146Gly either does not interact appropriately with actin or perhaps binds strongly to cTnC. The net effect would be lack of ATPase inhibition, in essence leaving the molecular switch in the "on" position. Decreased ATPase inhibition attributable to the R145G mutation supports this hypothesis. 27, 28 This model shows an accelerated disease course, with very early death noted at 13 to 17 days after birth in mice having Ϸ50% TG cTnI replacement. The original report of the R145G mutation provides scant clinical information regarding patient age at onset of symptoms, severity of hypertrophy, or life expectancy but did not emphasize a particularly malignant course. 1 This raises the question of why mice expressing this mutation seem to be more susceptible to cardiac dysfunction than humans. The answer may lie in the intrinsic chronotropic demands placed on the mouse heart, which must rapidly cycle through systole and diastole. The molecular switch between contraction and relaxation depends on precise molecular cooperation between thin and thick filament proteins, with the troponin complex serving as a molecular clutch. Intuitively, it would seem reasonable that as the heart cycles through systole and diastole at increasingly rapid rates, the margin of error for compromised protein interactions becomes ever smaller. The pathological outcome of an abnormal molecular switch would thus be more pro-nounced as intrinsic heart rate increases, with the most severe effects occurring at the shortest cycle lengths.
Sensitivity of the mouse heart to abnormal troponin proteins has been demonstrated in several experimental models. Targeted ablation of cTnI was temporarily compensated by expression of the neonatal (slow skeletal) isoform of TnI. 29 However, slow skeletal TnI expression gradually ceased, and the mice died at 18 days of age secondary to heart failure. Transgenic expression of a truncated cTnI associated with human myocardial stunning resulted in diminished contractility, decreased sensitivity to calcium, and ventricular enlargement. 30 Transgenic mice have also been used to model FHC-associated mutations in cardiac troponin T (cTnT). Human patients develop little or no ventricular hypertrophy yet have a high incidence of sudden death. When a cTnT mutation was transgenically expressed in mice, animals with Ͻ5% replacement of endogenous cTnT with mutated cTnT developed diastolic dysfunction, decreased ventricular mass, and myocyte disarray but had normal life spans. When these mice were bred to homozygosity, yielding animals that had Ϸ10% replacement, they uniformly died within 24 hours after birth, demonstrating that only small amounts of truncated cTnT could be tolerated by the mouse heart. 31 The mouse seems to be preferentially sensitive to several troponin mutations. Whether the TnI 146Gly mutation will be as virulent in a larger animal remains to be determined. Differential pathologies between mouse and human hypertrophic cardiomyopathy have been documented in other sarcomeric gene mutations. GeisterferLowrance et al 32 modeled the human ␤-MHC R403Q mutation in the mouse by making the corresponding mutation in the mouse ␣-MHC via gene targeting. Although the model demonstrated cardiomyocyte hypertrophy, interstitial fibrosis, and cardiomyocyte disarray, the ␣-MHC 403/ϩ mice had depressed cardiac output, a feature generally not seen in the human disease. Recently, a transgenic rabbit expressing the ␤-MHC R403Q mutation was created. 33 The rabbits accurately reproduced human FHC, demonstrating, in addition to the typical histological features of the disease, increased ventricular mass, preserved contractile function, and abnormal relaxation. The differences in phenotype between the mouse and rabbit experiments are not surprising given the distinctive biochemical properties of fast ␣-MHC and slow ␤-MHC. Our ability to specifically express transgenes in the rabbit heart has progressed rapidly, 34 and these mutations can be generated in the larger animals whose contractile apparatus more closely resembles that of the human. These experiments are underway. Figure 7 . pCa-force relationship curves of skinned fibers from ventricular papillary muscle. Fiber kinetics, including the pCAforce relationships, unloaded and maximum shortening velocity, and maximum relative power, were determined as described in Materials and Methods. Data were analyzed by one way ANOVA using Statview software (SAS Institute, Inc). The number of mixed-gender mice and the P0 (maximal tension expressed as mN/mm 2 ) is indicated. A, Line-133 TG and NTG at 9 days after birth. B, Line-52, line-121, and NTG controls at 6 weeks after birth. 
Working Heart Analysis
